Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2200143119
Abstract: Significance Pancreatic cancer is a leading cause of cancer-related death, in part due to incomplete responses to standard-of-care chemotherapy. In this study, using a combination of single-cell RNA sequencing and high-throughput proteomics, we identified the… read more here.
Keywords: pancreatic cancer; channel blockers; calcium channel; gemcitabine chemotherapy ... See more keywords
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature‐based meta‐analysis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12655
Abstract: The prognostic value of ribonucleotide reductase M1 (RRM1) in patients with pancreatic cancer receiving gemcitabine chemotherapy has been evaluated in several studies. However, the conclusions remain controversial. read more here.
Keywords: gemcitabine chemotherapy; cancer receiving; pancreatic cancer; patients pancreatic ... See more keywords
Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2022/4070060
Abstract: Objective This study aimed to investigate the efficacy and safety of anti-PD-1 immunotherapy combined with gemcitabine chemotherapy in multiline treatment of advanced pancreatic cancer. Methods A retrospective analysis was performed on the clinical data of… read more here.
Keywords: chemotherapy multiline; pancreatic cancer; gemcitabine chemotherapy; advanced pancreatic ... See more keywords